Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the publication of three podcasts with UroToday highlighting the company’s recent FDA approval of ANKTIVA® (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) and advances in bladder cancer research. Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific at ImmunityBio, discussed the breakin